<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/43B84FFA-A87D-4A61-8DBE-9A5DC2BE731F" ns1:id="43B84FFA-A87D-4A61-8DBE-9A5DC2BE731F"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/4B4EAAAE-D996-47C6-9BB2-DF52BB6393E1" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/88AAB194-D1BE-4056-A5D9-806CECC11CE1" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/88AAB194-D1BE-4056-A5D9-806CECC11CE1" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2027-07-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/B13DBCE8-E8D0-4397-AF33-43D237EDA479" ns1:rel="FUND" ns1:start="2026-02-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10146329</ns2:identifier></ns2:identifiers><ns2:title>Advanced Tissue Repair - Revolutionising Chronic&amp;nbsp;Wound&amp;nbsp;Care</ns2:title><ns2:status>Active</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Corryn is addressing urgent challenges of chronic wound care: one of the most critical unsolved medical challenges, with no satisfactory treatments for the 3.8m sufferers in the UK and 160m worldwide.

Our Advanced Tissue Repair (ATR) Platform is the world's first resorbable dressing (&amp;quot;the ATR Matrix&amp;quot;) to be fabricated directly at the wound using our novel &amp;quot;ATR Applicator&amp;quot;, eliminating painful re-dressings (with risks of infection, pain, scarring) and creating a unique scaffold that mimics the natural human extracellular matrix to uniquely promote wound healing.

This project will enable first-in-human trials, and will progress us towards regulatory approvals.</ns2:abstractText></ns2:project>